XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.19.1

6. Long-Term Debt | 3 Months Ended
--- | ---
Mar. 31, 2019
Debt Disclosure [Abstract] |
Long-term Debt | LONG-TERM DEBT The principal components of long-term debt are as follows (in millions):
| March 31, 2019 |  | December 31, 2018
4.875% Senior Notes due 2020 principal amount | $ | 425.0 |  |  | $ | 425.0 |
Less unamortized discount and debt issuance costs | (1.1 | ) |  | (1.3 | )
4.875% Senior Notes less unamortized discount and debt issuance costs | 423.9 |  |  | 423.7 |
Capital leases and other debt | — |  |  | 15.7 |
Finance leases and other debt | 15.5 |  |  | — |
| 439.4 |  |  | 439.4 |
Less current maturities | (1.8 | ) |  | (0.5 | )
Long-term debt | $ | 437.6 |  |  | $ | 438.9 |
Senior Notes due 2020 In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%. The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of March 31, 2019. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. Credit Agreement In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the 2014 Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the 2014 Credit Agreement as of March 31, 2019 or December 31, 2018, however $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of March 31, 2019. If we had borrowed against our 2014 Credit Agreement, the borrowing rate would have been 3.725% at March 31, 2019. The 2014 Credit Agreement was scheduled to mature in June 2019 but was renewed, and we entered into a new agreement in April 2019 for a maximum of $200.0 million on a revolving basis that will mature in April 2024. The 2019 Credit Agreement is substantially similar to the 2014 Credit Agreement. The borrowing rate for the 2019 Credit Agreement will be disclosed on a quarterly basis starting in the second quarter of 2019. The 2014 Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of March 31, 2019.

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for long-term debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -URI http://asc.fasb.org/topic&trid=2208564 + Details
Name: | us-gaap_LongTermDebtTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration